ClinicalTrials.gg
CompletedNCT01791153Updated Feb 6, 2020Results posted

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

A Phase 3 interventional study of Tocilizumab and Prednisone in Giant Cell Arteritis, sponsored by Hoffmann-La Roche. Completed at 78 sites in 14 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-02-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tocilizumab in Giant Cell Arteritis — 2 open to participants now, 3 under way, 1 of them phase 3. tocilizumab · Giant Cell Arteritis.

Enrollment
2nd of 12
251 · median 44
Started
2013
the only one that year
Phase 3
3 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
3 of 12
Hoffmann-La Roche

Among the 12 studies testing tocilizumab in Giant Cell Arteritis, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 2nd registered.

Giant Cell Arteritis

149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.

Browse Giant Cell Arteritis studies →

Open to participants now

2 of the 12 studies testing tocilizumab in Giant Cell Arteritis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tocilizumab in Giant Cell Arteritis, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA. The study will consist of 2 parts: a 52-week double-blind treatment period (Part 1) followed by a 104-week open label long-term follow-up period (Part 2). In Part 1 of the study eligible participants will be randomized to receive either tocilizumab every week (qw) or every 2 weeks (q2w) or placebo for 52 weeks, with tapering oral daily doses of prednisone. After Week 52, participants in remission will stop study treatment and enter long-term follow-up, whereas participants with disease activity or flares will receive open-label tocilizumab or other treatment at the discretion of the investigator for a maximum period of 104 weeks.

03

Conditions studied

  • Giant Cell Arteritis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of GCA classified according to age >/=50 years; history of ESR >/=50 mm/hr or history of CRP >/=2.45 mg/dL; and at least one of the following: unequivocal cranial symptoms of GCA or symptoms of polymyalgia rheumatica [PMR]; and at least one of the following: temporal artery revealing features of GCA or evidence of large-vessel vasculitis by angiography or cross-sectional imaging
  • New onset (diagnosis within 6 weeks of baseline) or (diagnosis greater than [>] 6 weeks before baseline and previous treatment with >/= 40 milligrams per day prednisone [or equivalent] for at least 2 consecutive weeks at any time) GCA
  • Active disease (presence of clinical signs and symptoms [cranial or PMR] and ESR >/=30 mm/hour or CRP >/=1 mg/dL) within 6 weeks of baseline visit

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 8 weeks prior to screening or planned within 12 months after randomization
  • Transplanted organs (except corneas with transplant performed >3 months prior to screening)
  • Major ischemic event, unrelated to GCA, within 12 weeks of screening
  • Prior treatment with any of the following: agent within 12 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening; cell-depleting therapies including investigational agent; intravenous (IV) gamma globulin or plasmapheresis within 6 months of baseline; alkylating agents or with total lymphoid irradiation; tocilizumab; hydroxychloroquine, cyclosporine A, azathioprine, or mycophenolate mofetil within 4 weeks of baseline; etanercept within 2 weeks of baseline; infliximab, certolizumab, golimumab, abatacept, or adalimumab within 8 weeks of baseline; anakinra within 1 week of baseline; tofacitinib; cyclophosphamide within 6 months of baseline; >100 milligrams of daily IV methylprednisolone within 6 weeks of baseline
  • Participants requiring systemic for conditions other than GCA, which, in the opinion of the investigator, would interfere with adherence to the fixed glucocorticoid taper regimen and/or to assessment of efficacy in response to the test article
  • History of severe allergic reactions to monoclonal antibodies or to prednisone
  • Evidence of serious uncontrolled concomitant disease (for example, cardiovascular, respiratory, renal, endocrine, psychiatric, corneal ulcers/injuries, or gastrointestinal [GI] disease)
  • Current liver disease, as determined by the investigator
  • History of diverticulitis, inflammatory bowel disease, or other symptomatic GI tract condition that might predispose to bowel perforation
  • Known active or history of recurrent bacterial, viral fungal, mycobacterial, or other infection
  • Primary or secondary immunodeficiency
  • Evidence of diagnosed within previous 5 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that have been excised and cured)
  • Inadequate hematologic, renal or liver function
  • Positive for or infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Part 1: Tocilizumab qw + 26 weeks prednisone taper

    Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.

    Drug: Tocilizumab · Drug: Prednisone · Drug: Prednisone Placebo

  • Experimental
    Part 1: Tocilizumab q2w + 26 weeks prednisone taper

    Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.

    Drug: Tocilizumab · Drug: Prednisone · Drug: Tocilizumab Placebo · Drug: Prednisone Placebo

  • Placebo comparator
    Part 1: Placebo + 26 weeks prednisone taper

    Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.

    Drug: Prednisone · Drug: Tocilizumab Placebo · Drug: Prednisone Placebo

  • Placebo comparator
    Part 1: Placebo + 52 weeks prednisone taper

    Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.

    Drug: Prednisone · Drug: Tocilizumab Placebo · Drug: Prednisone Placebo

  • Experimental
    Part 2: Open-Label Tocilizumab qw

    Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.

    Drug: Tocilizumab · Drug: Corticosteroids · Drug: Methotrexate

Interventions

  • Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.

    Also known as: RoActemra, Actemra, RO4877533

  • Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.

  • DrugTocilizumab Placebo

    Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.

  • DrugPrednisone Placebo

    Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.

  • DrugCorticosteroids

    Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.

  • Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)

    Remission was defined as the absence of flare and normalization of the C-reactive protein (CRP) (less than \[\<\] 1 milligram per deciliter \[mg/dL\]). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or erythrocyte sedimentation rate (ESR) greater than or equal to (\>/=) 30 millimeters per hour (mm/hr) attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)

    Remission was defined as the absence of flare and normalization of the CRP (\<1 mg/dL). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.

    Time frame: Week 52

  2. Time to First GCA Disease Flare

    Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. Participants who withdrew from the study prior to Week 52 were censored from the time of withdrawal.

    Time frame: Up to 52 weeks

  3. Total Cumulative Prednisone Dose

    The median total cumulative prednisone dose over the 52 weeks for each treatment group and the corresponding 95% confidence intervals are presented.

    Time frame: Up to 52 weeks

  4. Change From Baseline in Short Form (SF)-36 Questionnaire Score at Week 52

    The SF-36 is a standardized questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Score (PCS) and Mental Component Score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A positive change from baseline indicates improvement. No imputation was used for missing data. Data was set to missing for participants who received escape therapy.

    Time frame: Baseline, Week 52

  5. Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Assessed Using Visual Analogue Scale (VAS) at Week 52

    Participants assessed their current disease activity on a 0-100 millimeter (mm) VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 52

  6. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab

    AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval. AUCtau is measured in microgram\*day per milliliter (mcg\*day/mL).

    Time frame: Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])

  7. Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab

    Cmax,ss is maximum model-predicted serum steady state concentration of tocilizumab measured in micrograms per milliliter (mcg/mL).

    Time frame: Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])

  8. Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab

    Cmin,ss is minimum model-predicted serum steady state concentration of tocilizumab measured in mcg/mL.

    Time frame: Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])

  9. Minimum Observed Serum Concentration (Ctrough) of Tocilizumab

    Ctrough is minimum observed serum concentration of tocilizumab measured in mcg/mL.

    Time frame: Predose (Hour 0) at Baseline and Week 52

  10. Serum Interleukin-6 (IL-6) Level

    Time frame: Baseline and Week 52

  11. Serum Soluble IL-6 Receptor (sIL-6R) Level

    Time frame: Baseline and Week 52

  12. Erythrocyte Sedimentation Rate (ESR)

    ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.

    Time frame: Baseline and Week 52

  13. C-Reactive Protein (CRP) Level

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: Baseline and Week 52

  14. Percentage of Participants With Anti-Tocilizumab Antibodies

    All samples were tested by screening assay, and those samples that were positive were further analyzed by a confirmation assay to confirm specificity. Percentage of participants who has a positive confirmation assay result any time after the initial drug administration with a negative confirmation assay result at baseline was reported.

    Time frame: Baseline up to Week 52

07

Results

Posted May 18, 2017

Participant flow

The study consists of 2 parts: a 52-week double-blind treatment period (Part 1) followed by a 104-week open label long-term follow-up period (Part 2).

Part 1: Blinded Period
Participant flow — Part 1: Blinded Period
MilestonePart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone TaperPart 2: No Tocilizumab (Placebo in Part 1)Part 2: No Tocilizumab (Tocilizumab in Part 1)Part 2: Tocilizumab (Placebo in Part 1)Part 2: Tocilizumab (Tocilizumab in Part 1)
Started1004950510000
Completed854144460000
Not completed158650000
Withdrew: Adverse event73200000
Withdrew: Lack of efficacy13220000
Withdrew: Non-compliance10000000
Withdrew: Physician decision00010000
Withdrew: Protocol violation00010000
Withdrew: Withdrawal by subject62210000
Part 2: Open-label Period
Participant flow — Part 2: Open-label Period
MilestonePart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone TaperPart 2: No Tocilizumab (Placebo in Part 1)Part 2: No Tocilizumab (Tocilizumab in Part 1)Part 2: Tocilizumab (Placebo in Part 1)Part 2: Tocilizumab (Tocilizumab in Part 1)
Started000040585067
Completed000038544461
Not completed00002466
Withdrew: Adverse event00000112
Withdrew: Death00000111
Withdrew: Lost to follow-up00000010
Withdrew: Lack of efficacy00000001
Withdrew: Withdrawal by subject00001132
Withdrew: Physician decision00001100

Outcome measures

PrimaryPercentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)

Remission was defined as the absence of flare and normalization of the C-reactive protein (CRP) (less than \[\<\] 1 milligram per deciliter \[mg/dL\]). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or erythrocyte sedimentation rate (ESR) greater than or equal to (\>/=) 30 millimeters per hour (mm/hr) attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)
percentage of participantsPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone Taper
Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)56.053.114.0
Statistical analysis
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response rates: 42.00 · 99.5% CI 18.00 to 66.00
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Cochran-Mantel-Haenszel · p = < 0.0001 · Difference in response rates: 39.06 · 99.5% CI 12.46 to 65.66
SecondaryPercentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)

Remission was defined as the absence of flare and normalization of the CRP (\<1 mg/dL). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)
percentage of participantsPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)56.053.117.6
Statistical analysis
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Cochran-Mantel-Haenszel · p = < 0.0001
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Difference in response rates: 38.35 · 99.5% CI 17.89 to 58.81
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Cochran-Mantel-Haenszel · p = 0.0002
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Difference in response rates: 35.41 · 99.5% CI 10.41 to 60.41
SecondaryTime to First GCA Disease Flare

Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. Participants who withdrew from the study prior to Week 52 were censored from the time of withdrawal.

Time frame:
Up to 52 weeks
Reported as:
Median · days
Time to First GCA Disease Flare
daysPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Time to First GCA Disease FlareNA (NA to NA)NA (NA to NA)165.0 (120.0 to 260.0)295.0 (168.0 to NA)
Statistical analysis
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Cox proportional hazards model · p = <0.0001 · Hazard ratio (hr): 0.23 · 99% CI 0.11 to 0.46
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Cox proportional hazards model · p = 0.0011 · Hazard ratio (hr): 0.39 · 99% CI 0.18 to 0.82
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Cox proportional hazards model · p = 0.0001 · Hazard ratio (hr): 0.28 · 99% CI 0.12 to 0.66
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Cox proportional hazards model · p = 0.0316 · Hazard ratio (hr): 0.48 · 99% CI 0.20 to 1.16
SecondaryTotal Cumulative Prednisone Dose

The median total cumulative prednisone dose over the 52 weeks for each treatment group and the corresponding 95% confidence intervals are presented.

Time frame:
Up to 52 weeks
Reported as:
Median · milligrams (mg)
Total Cumulative Prednisone Dose
milligrams (mg)Part 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Total Cumulative Prednisone Dose1862.00 (1582.0 to 1942.0)1862.00 (1568.0 to 2239.5)3296.00 (2729.5 to 4023.5)3817.50 (2817.5 to 4425.5)
Statistical analysis
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Van Elteren's test · p = <0.0001
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Van Elteren's test · p = <0.0001
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Van Elteren's test · p = 0.0003
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Van Elteren's test · p = <0.0001
SecondaryChange From Baseline in Short Form (SF)-36 Questionnaire Score at Week 52

The SF-36 is a standardized questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Score (PCS) and Mental Component Score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A positive change from baseline indicates improvement. No imputation was used for missing data. Data was set to missing for participants who received escape therapy.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Short Form (SF)-36 Questionnaire Score at Week 52
units on a scalePart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
PCS: Baseline (n=97,49,48,49)43.10 ± 9.4340.62 ± 8.0042.65 ± 10.8741.12 ± 9.97
PCS: Change at Week 52 (n=59,26,9,18)5.37 ± 7.382.71 ± 8.862.08 ± 12.11-2.80 ± 6.98
MCS: Baseline (n=97,49,48,49)42.77 ± 12.4347.67 ± 12.5942.73 ± 12.1340.45 ± 13.73
MCS: Change at Week 52 (n=59,26,9,18)8.21 ± 10.351.98 ± 7.174.99 ± 7.542.60 ± 10.56
Statistical analysis
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Repeated measures model · p = 0.8067 · Difference in least square means: 0.61 · 99% CI -5.86 to 7.07
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Repeated measures model · p = 0.0252 · Difference in least square means: 4.44 · 99% CI -0.69 to 9.56
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Repeated measures model · p = 0.8374 · Difference in least square means: -0.56 · 99% CI -7.64 to 6.53
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Repeated measures model · p = 0.1468 · Difference in least square means: 3.27 · 99% CI -2.59 to 9.14
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Repeated measures model · p = 0.0570 · Difference in least square means: 4.38 · 99% CI -1.58 to 10.34
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Repeated measures model · p = 0.0024 · Difference in least square means: 5.59 · 99% CI 0.86 to 10.32
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Repeated measures model · p = 0.2218 · Difference in least square means: 3.04 · 99% CI -3.43 to 9.51
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Repeated measures model · p = 0.0412 · Difference in least square means: 4.25 · 99% CI -1.14 to 9.64
SecondaryChange From Baseline in Patient Global Assessment (PGA) of Disease Activity Assessed Using Visual Analogue Scale (VAS) at Week 52

Participants assessed their current disease activity on a 0-100 millimeter (mm) VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 52
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Assessed Using Visual Analogue Scale (VAS) at Week 52
mmPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Baseline (n=100,49,49,51)43.61 ± 25.6646.65 ± 25.6035.73 ± 28.1547.78 ± 27.80
Change at Week 52 (n=60,26,11,18)-19.68 ± 33.64-22.69 ± 22.41-8.45 ± 24.81-10.00 ± 35.12
Statistical analysis
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Repeated measures model · p = 0.0312 · Difference in least square means: -15.6 · 99% CI -34.3 to 3.1
  • Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Repeated measures model · p = 0.0476 · Difference in least square means: -11.8 · 99% CI -27.2 to 3.6
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 26 Weeks Prednisone Taper · Repeated measures model · p = 0.0059 · Difference in least square means: -21.9 · 99% CI -42.4 to -1.4
  • Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper vs Part 1: Placebo + 52 Weeks Prednisone Taper · Repeated measures model · p = 0.0081 · Difference in least square means: -18.2 · 99% CI -35.8 to -0.5
SecondaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab

AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval. AUCtau is measured in microgram\*day per milliliter (mcg\*day/mL).

Time frame:
Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])
Reported as:
Mean · mcg*day/mL
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab
mcg*day/mLPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone Taper
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab499.2 ± 210.4227.2 ± 165.4
SecondaryMaximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab

Cmax,ss is maximum model-predicted serum steady state concentration of tocilizumab measured in micrograms per milliliter (mcg/mL).

Time frame:
Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])
Reported as:
Mean · mcg/mL
Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab
mcg/mLPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone Taper
Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab73 ± 30.419.3 ± 12.8
SecondaryMinimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab

Cmin,ss is minimum model-predicted serum steady state concentration of tocilizumab measured in mcg/mL.

Time frame:
Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])
Reported as:
Mean · mcg/mL
Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab
mcg/mLPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone Taper
Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab68.1 ± 29.511.1 ± 10.3
SecondaryMinimum Observed Serum Concentration (Ctrough) of Tocilizumab

Ctrough is minimum observed serum concentration of tocilizumab measured in mcg/mL.

Time frame:
Predose (Hour 0) at Baseline and Week 52
Reported as:
Mean · mcg/mL
Minimum Observed Serum Concentration (Ctrough) of Tocilizumab
mcg/mLPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone Taper
Baseline (n= 99, 48)0.07 ± 0.720.00 ± 0.02
Week 52 (n= 72, 33)67.93 ± 34.4012.22 ± 10.02
SecondarySerum Interleukin-6 (IL-6) Level
Time frame:
Baseline and Week 52
Reported as:
Mean · picograms per milliliter (pg/mL)
Serum Interleukin-6 (IL-6) Level
picograms per milliliter (pg/mL)Part 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Baseline (n=91,44,50,47)8.79 ± 10.0116.29 ± 31.2312.73 ± 18.048.31 ± 9.47
Week 52 (n=69,32,28,30)65.99 ± 84.9252.70 ± 33.1035.96 ± 149.6510.85 ± 15.17
SecondarySerum Soluble IL-6 Receptor (sIL-6R) Level
Time frame:
Baseline and Week 52
Reported as:
Mean · nanograms per milliliter (ng/mL)
Serum Soluble IL-6 Receptor (sIL-6R) Level
nanograms per milliliter (ng/mL)Part 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Baseline (n=99,48,50,50)51.34 ± 61.9850.82 ± 63.5142.07 ± 11.3240.37 ± 10.84
Week 52 (n=73,33,33,31)600.53 ± 217.52464.30 ± 153.6476.44 ± 149.2064.80 ± 105.13
SecondaryErythrocyte Sedimentation Rate (ESR)

ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.

Time frame:
Baseline and Week 52
Reported as:
Median · mm/hr
Erythrocyte Sedimentation Rate (ESR)
mm/hrPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Baseline (n=99,49,50,51)19.00 ± 61.9815.00 ± 63.5123.00 ± 11.3220.00 ± 10.84
Week 52 (n=76,35,35,33)3.00 (2.00 to 5.00)5.00 (2.00 to 7.00)20.00 (11.00 to 36.00)24.00 (10.00 to 37.00)
SecondaryC-Reactive Protein (CRP) Level

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
Baseline and Week 52
Reported as:
Median · milligrams per liter (mg/L)
C-Reactive Protein (CRP) Level
milligrams per liter (mg/L)Part 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Baseline (n=100,49,50,51)3.67 ± 61.984.52 ± 63.513.64 ± 11.323.56 ± 10.84
Week 52 (n=76,35,35,33)0.30 (0.20 to 0.59)0.33 (0.20 to 0.72)4.90 (2.25 to 9.25)8.12 (2.02 to 14.40)
SecondaryPercentage of Participants With Anti-Tocilizumab Antibodies

All samples were tested by screening assay, and those samples that were positive were further analyzed by a confirmation assay to confirm specificity. Percentage of participants who has a positive confirmation assay result any time after the initial drug administration with a negative confirmation assay result at baseline was reported.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Tocilizumab Antibodies
percentage of participantsPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone Taper
Percentage of Participants With Anti-Tocilizumab Antibodies1.16.52.02.1

Adverse events

Collected over Up to 156 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper—15/100 (15%)87/100 (87%)
Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper—7/49 (14.3%)44/49 (89.8%)
Part 1: Placebo + 26 Weeks Prednisone Taper—11/50 (22%)47/50 (94%)
Part 1: Placebo + 52 Weeks Prednisone Taper—13/51 (25.5%)44/51 (86.3%)
Part 2: No Tocilizumab (Placebo in Part 1)—7/40 (17.5%)33/40 (82.5%)
Part 2: No Tocilizumab (Tocilizumab in Part 1)—11/58 (19%)50/58 (86.2%)
Part 2: Tocilizumab (Placebo in Part 1)—18/50 (36%)44/50 (88%)
Part 2: Tocilizumab (Tocilizumab in Part 1)—23/67 (34.3%)61/67 (91%)
Most frequent serious events
Showing 10 of 121
Most frequent serious events
EventPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone TaperPart 2: No Tocilizumab (Placebo in Part 1)Part 2: No Tocilizumab (Tocilizumab in Part 1)Part 2: Tocilizumab (Placebo in Part 1)Part 2: Tocilizumab (Tocilizumab in Part 1)
Temporal arteritisVascular disorders1/1001/491/501/511/400/582/503/67
UrosepsisInfections and infestations1/1000/490/500/510/400/582/500/67
Cerebrovascular accidentNervous system disorders0/1000/490/500/510/400/582/500/67
GastroenteritisInfections and infestations1/1000/490/502/510/401/580/500/67
Herpes zosterInfections and infestations1/1000/490/502/510/400/580/500/67
OsteoarthritisMusculoskeletal and connective tissue disorders0/1000/490/501/510/401/580/502/67
HaematomaVascular disorders0/1000/490/500/510/400/580/502/67
GlaucomaEye disorders0/1000/491/500/511/400/580/500/67
SyncopeNervous system disorders0/1000/491/500/511/401/580/501/67
Cardiac failureCardiac disorders0/1000/490/501/511/400/580/501/67
Most frequent other events
Showing 10 of 82
Most frequent other events
EventPart 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone TaperPart 2: No Tocilizumab (Placebo in Part 1)Part 2: No Tocilizumab (Tocilizumab in Part 1)Part 2: Tocilizumab (Placebo in Part 1)Part 2: Tocilizumab (Tocilizumab in Part 1)
NasopharyngitisInfections and infestations29/10012/499/5013/515/4013/5814/5022/67
HeadacheNervous system disorders27/10010/4916/5012/512/408/588/506/67
Oedema peripheralGeneral disorders16/10012/498/506/511/402/585/504/67
DizzinessNervous system disorders6/10010/496/508/512/400/585/504/67
Urinary tract infectionInfections and infestations10/1004/492/504/511/404/5810/5010/67
ArthralgiaMusculoskeletal and connective tissue disorders13/1008/4910/508/517/4010/5810/5012/67
Back painMusculoskeletal and connective tissue disorders14/1007/497/5010/513/404/588/507/67
DiarrhoeaGastrointestinal disorders12/1003/498/505/512/402/587/505/67
FatigueGeneral disorders8/1005/498/503/512/402/586/506/67
Oropharyngeal painRespiratory, thoracic and mediastinal disorders7/1004/494/508/512/402/582/504/67

Baseline characteristics

Safety Population included all participants who received at least one administration of study drug and provided at least one post-dose safety assessment.

Age, Continuous
Age, Continuous(years)Part 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone TaperTotal
Mean69.5 ± 8.5069.4 ± 8.2969.3 ± 8.1467.8 ± 7.7069.1 ± 8.21
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Tocilizumab qw + 26 Weeks Prednisone TaperPart 1: Tocilizumab q2w + 26 Weeks Prednisone TaperPart 1: Placebo + 26 Weeks Prednisone TaperPart 1: Placebo + 52 Weeks Prednisone TaperTotal
Female78343837187
Male2215121463
08

Study locations

78 sites
  • Univ of Calif., Los Angeles; Rheumatology
    Los Angeles, California 90025, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Rheumatology Assoc. of S. Florida - Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Sarasota Arthritis Res Center
    Sarasota, Florida 34239, United States
  • Four Rivers Clinical Research Inc.
    Paducah, Kentucky 42003, United States
  • Rheumatology Associates
    Portland, Maine 04102, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Shores Rheumatology
    Saint Clair Shores, Michigan 48081, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Hospital For Special Surgery; Dept of Medicine - Rheumatology
    New York, New York 10021, United States
  • Asheville Arthritis & Osteoporosis Center, PA
    Asheville, North Carolina 28803, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Utah; Division of Rheumatology
    Salt Lake City, Utah 84132, United States
  • Marshfield Clinic Wausau Ctr
    Wausau, Wisconsin 54401, United States
  • Hospital Erasme
    Bruxelles, 1070, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Clin. de Rhumatologie
    Trois-rivieres, Quebec G8Z 1Y2, Canada
  • Nordsjællands Hospital - Hillerød;Department of Rheumatology 0731
    Hillerod, 3400, Denmark
  • Hopital Avicenne; Medecine Interne H5
    Bobigny, 93009, France
  • Hopital La Cavale Blanche; Rhumatologie
    Brest, 29609, France
  • Hopital Claude Huriez; Internal Medicine
    Lille, 59037, France
  • Hôpital de la Conception
    Marseille, 13000, France
  • Hopital Emile Muller; Medecine Interne
    Mulhouse, 68070, France
  • Hopital Cochin; Medecine Interne
    Paris, 75679, France
  • Asklepios Kllinikum Bad Abbach; Klinik für Rheumatologie und Klinische Immunologie
    Bad Abbach, 93077, Germany
  • Rheuma-Klinikum Bad Bramstedt Klinik fuer Rheumatologie und Immunologie
    Bad Bramstedt, 24576, Germany
  • Charité Campus Mitte, Med.Klinik, Rheumatologie und Klinische Immunologie
    Berlin, 10117, Germany
  • Schlosspark Klinik; Abt. Rheumatologie
    Berlin, 14059, Germany
  • Universitätsklinikum "Carl Gustav Carus"; Medizinische Klinik III
    Dresden, 01307, Germany
  • Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie
    Erlangen, 91054, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Medizinische Hochschule Zentrum Innere Medizin Abt.Klinische Immunologie und Rheumatologie
    Hannover, 30625, Germany
  • Rheumazentrum-Ruhrgebiet, St. Josefs-Krankenhaus; Rheumatologie
    Herne, 44652, Germany
  • Universitätsklinikum Jena; Klinik für Innere Medizin III
    Jena, 07747, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie
    Mainz, 55131, Germany
  • Klinikum der Universitat Munchen; Bereich Pettenkoferstr; Rheumaeinheit der medizinischen Klinik IV
    München, 80336, Germany
  • Kreiskliniken Esslingen gGmbH Klinik Plochingen Medizinische Klinik
    Plochingen, 73207, Germany
  • Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II
    Tübingen, 72076, Germany
  • Arcispedale Santa Maria Nuova; Reumatologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Policlinico Univ. Uni Degli Sudi Di Udine; Clinica Di Reumatologia
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Università Degli Studi Di Genova - Dimi; Reumatologia
    Genova, Liguria 16132, Italy
  • Irccs San Raffele; Div Med Gen Immunologia Clinica
    Milano, Lombardia 20132, Italy
  • A.O. Universitaria Pisana; Psichiatria
    Pisa, Toscana 56126, Italy
  • Azienda Ospedaliera di Padova; Cattedra e Divisione di Reumatologia
    Padova, Veneto 35128, Italy
  • Azienda Ospedaliera di Verona-Ospedale Civile Maggiore
    Verona, Veneto 37126, Italy
  • VU Medisch Centrum; Reumatologie 4-A-A2
    Amsterdam, 1081 HV, Netherlands
  • Ziekenhuis Rijnstate
    Arnhem, 6815 AD, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Ziekenhuisgroep Twente, Hengelo
    Hengelo, 7555 DL, Netherlands
  • Akademisch Ziekenhuis St. Radboud; Rheumatology
    Nijmegen, 6525 GA, Netherlands
  • Sørlandet Sykehus Kristiansand
    Kristiansand, 4604, Norway
  • Rikshospitalet; Revmatologisk Avd Seksjon Barnerevmatologi
    Oslo, 0027, Norway
  • Ålesund sjukehus
    Ålesund, N-6026, Norway
  • Szpital Uniwersytecki; nr 2 im. Dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Klinika Reumatologii I Chorób Wewn. Pum W Szczecinie; Samodzielny Publiczny Szpital Kliniczny Nr 1
    Szczecin, 71-252, Poland
  • Hospital Geral de Santo Antonio; Servico de Imunologia Clinica
    Porto, 4099-001, Portugal
  • Hospital Univ A Coruna; Rheumatology
    A Coruna, LA Coruña 15006, Spain
  • Hospital Universitario de Canarias;servicio de Reumatologia
    La Laguna, Tenerife 38320, Spain
  • Hospital de Basurto; Servicio de Reumatologia
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitari de Bellvitge; Servicio de Reumatologia
    Barcelona, 08907, Spain
  • University of Barcelona; Dept. of Internal Medicine,
    Barcelona, 8036, Spain
  • Sahlgrenska Universitetssjukhuset
    Goteborg, 413 45, Sweden
  • Skånes Universitetssjukhus
    Lund, 221 85, Sweden
  • Skånes Universitetssjukhus Malmö; Reumatologkliniken
    Malmo, 205 02, Sweden
  • Karolinska Sjukhuset; Reumatologkliniken D2-1
    Stockholm, 171 76, Sweden
  • Akademiska Sjukhuset; Lungmedicinska Kliniken
    Uppsala, 751 85, Sweden
  • Aberdeen Royal Infirmary; Medical Oncology Dept
    Aberdeen, AB25 2ZN, United Kingdom
  • Barnsley General Hospital; Rheumatology
    Barnsley, S75 2EP, United Kingdom
  • Old Queen Elizabeth Hospital; Pharmacy Building;Clinical Research offices
    Birmingham, B15 2TH, United Kingdom
  • Colchester General Hospital; Aseptic Dept, Pharmacy Support Unit
    Colchester, Essex, CO4 5JL, United Kingdom
  • University of Edinburgh; The Queens Medical Research Institute
    Edinburgh, EH16 4TJ, United Kingdom
  • CHAPEL ALLERTON HOSPITAL; Unit of Musculoskeletal Disease
    Leeds, LS7 4SA, United Kingdom
  • Moorfields Eye Hospital NHS Foundation Trust
    London, EC1V 2PD, United Kingdom
  • Freeman Hospital; Dept of Rheumatology
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Queen's Hospital
    Romford, RM7 0AG, United Kingdom
  • Haywood Hospital; Staffordshire Rheumatology Centre
    Stoke-on-trent, ST6 7AG, United Kingdom
  • Royal Cornwall Hospital; Rhuematololgy Dept
    Truro, TR1 3LJ, United Kingdom
  • Southend Hospital; Rheumatology Department
    Westcliffe-on-sea, SS0 0RY, United Kingdom
09

References and documents

Publications

  • Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2022 Jul 6;61(7):2915-2922. doi: 10.1093/rheumatology/keab780. PubMed 34718434 ↗
  • Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis. 2021 Nov;80(11):1467-1474. doi: 10.1136/annrheumdis-2021-220347. Epub 2021 May 28. PubMed 34049857 ↗
  • Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol. 2019 Aug;71(8):1329-1338. doi: 10.1002/art.40876. Epub 2019 Jul 3. PubMed 30835950 ↗
  • Strand V, Dimonaco S, Tuckwell K, Klearman M, Collinson N, Stone JH. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. Arthritis Res Ther. 2019 Feb 20;21(1):64. doi: 10.1186/s13075-019-1837-7. PubMed 30786937 ↗
  • Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849. PubMed 28745999 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2013 to primary completion in Apr 2016, 32 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2013
First posted
Feb 13, 2013
StartActual
Jul 22, 2013
Primary completionActual
Apr 11, 2016
CompletionActual
Jun 4, 2018
Results first posted
May 18, 2017
Last update
Feb 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01791153
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 13, 2013
Start date
Jul 22, 2013
Primary completion
Apr 11, 2016
Completion
Jun 4, 2018
Results posted
May 18, 2017
Last update
Feb 6, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Prednisone

Start the discussion